Characterization of acute myocardial infarction in Venezuela during 2008
Keywords:
acute coronary syndrome, acute myocardial infarction, thrombolysis, streptokinaseAbstract
A cross-sectional, descriptive and observational study was carried out in order to characterize the acute myocardial infarction in the Intensive Care Units of the first Integral Diagnosis Centers inaugurated by the Barrio Adentro Mission in the Bolivarian Republic of Venezuela, since the implementation of the first Integral Medical Centers in 2008. A total of 240 patients with an acute myocardial infarction diagnosis were assisted. There was a predominance of the male patients and the white color of the skin. The stay of the patients at the Intensive Care Unit was of more than 7 days; and among the risk factors, the most prevalent one was dyslipidemia. Concerning the topography of the infarction, the most common was the anterior wall infarction. The general survival was much higher in the cases that received the thrombolytic therapy and the normal procedures of vital support.
Downloads
References
1. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410-4.
2. Gurfinque G, Santos A. Hacia el diagnóstico de angina inestable. Rev Esp Cardiol. 2005;(53):1159-63.
3. Bazzino O, Díaz R, Tajer C, Paviotti C, Mele E, Trivi M, et al. Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. The ECLA Collaborative Group. Am Heart J. 1999;137(2):322-31.
4. Cuba, Ministerio de Salud Pública. Dirección Nacional de Estadística. Informe Anual Estadísticas Vitales. Ciudad de La Habana: MINSAP; 1995.
5. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88:2045-48.
6. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithombotic therapy in resting angina or no Q ware myocardial infarction therapy, Antithrombotic Therapy in acute coronary syndrome study group. Am J Cardiol. 1990;66(19):1287-92.
7. Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, et al. rison of Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol. 2004;93(7):843-7.
8. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med. 1998;338(21):1498-505.
9. Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, et al. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002;14(1):33-42.
10. Chang WC, Harrington RA, Simoons ML, Califf RM, Lincoff AM, Armstrong PW. Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. Eur Heart J. 2002;23(14):1102-11.
11. James S, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med. 2003;115(3):178-84.
12. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888-94.
13. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6921):81-106.
14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
15. Cairns JA, Théroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001;120(4):1427.
16. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-89.
17. Stone GW, Grines CL, Cox DA, García E, Tcheng JE, Griffin JJ, et al. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. N Engl J Med. 2002;346(13): 957-66.
18. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A ramdomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42(11):1879-85.
19. Simoons ML, The Gusto IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001; 357(9272):1915-24.
20. Klein W, Buchwald A, Hillis ES, Monrad S, Sanz G, Graham AG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997;96(1):61-8.
21. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358(9282):605-13.
22. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-62.
23. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43(10):1773-9.
24. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2003;24(12):1174-5.
25. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Task Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24(1):28-66.
26. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-8.
27. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16.
28. Boersma E, Mercado N, Poldersman D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet. 2003;361(9360):847-58.
29. Rawlws J. GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis. Heart 2003;89(5): 563-4.
30. Abildstrom SZ, Rasmussen S, Rosen M, Madsen M. Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart. 2003 ;89(5):507-11.
31. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40(7):1366-74.
32. Brian W, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation. 2005;111(20): 2699-710.
Downloads
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
